西罗莫司市场 - 按应用（器官移植排斥、淋巴管平滑肌瘤病）、给药途径（注射、片剂）、剂量（0.5毫克、1毫克、2毫克）、配销通路（医院药房、零售药局） - 全球预测（2024年- 2032年）

西罗莫司市场规模预计在2024 年至2032 年间将以3.6% 的复合年增长率扩大。的增长。癌症、淋巴管平滑肌瘤病 (LAM) 和冠状动脉疾病等各种疾病的盛行率不断上升，刺激了对西罗莫司疗法的需求。

根据联合器官共享网路的资料，2023年美国进行了超过46,000例器官移植。正在进行的研究西罗莫司治疗各种疾病功效的临床试验正在增加其市场吸引力。药物传输技术的重大进步和仿製药的引入正在提高可及性和可负担性，进一步推动西罗莫司药物的广泛采用。

西罗莫司产业分为应用、给药途径、剂量、配销通路和地区。

根据应用，淋巴管平滑肌瘤病(LAM) 领域的市场规模预计在2024 年至2032 年间将以3.4% 的复合年增长率增长。女性的罕见进行性肺部疾病。西罗莫司已被证明可以稳定 LAM 患者的肺功能并减轻症状。人们越来越认识到西罗莫司作为 LAM 的治疗选择，以及正在进行的临床研究将进一步推动该细分市场的成长。

就给药途径而言，由于对标靶和控制药物传递的需求不断增长，特别是在需要免疫抑制的移植患者中，注射领域的西罗莫司行业到2032年的复合年增长率将达到3.8 %。西罗莫司的注射製剂可提供精确的剂量和快速起效，使其适合移植后护理。这些注射也确保药物的全身分布，优化治疗结果。注射技术的显着进步提高了患者的便利性和依从性，将促进该细分市场的成长。

从区域来看，由于需要免疫抑制治疗的慢性疾病（包括器官移植和自体免疫疾病）盛行率不断上升，预计欧洲西罗莫司市场从 2024 年到 2032 年将增加 3.2%。此外，该地区在肿瘤学领域也越来越多地采用西罗莫司来治疗各种癌症。此外，政府支持器官捐赠和移植的有利倡议，加上医疗基础设施的进步，将进一步刺激该地区对西罗莫司药物的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 器官移植发生率上升
    • 针对不同适应症的有前途的管道
    • 药物输送系统的进步
  • 产业陷阱与挑战
    • 与西罗莫司相关的不良反应
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 器官移植排斥反应
• 淋巴管平滑肌瘤病 (LAM)
• 西罗莫司涂层球囊和导管装置

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 注射
• 平板电脑

第 7 章：市场估计与预测：按剂量，2021-2032

• 主要趋势
• 0.5毫克
• 1毫克
• 2毫克

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Accord Healthcare Limited
• Apotex Inc.
• Amneal Pharmaceuticals, Inc.
• Actiza Pharmaceutical Private Limited
• Biocon Limited
• Concept Medical
• Concord Biotech
• Dr. Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Ltd.
• Livzon Pharmaceuticals Group Inc.
• Pfizer Inc.
• Tiefenbacher API + Ingredients GmbH & Co. KG
• Torrent Pharmaceuticals Ltd.
• Zydus Group

Sirolimus Market size is estimated to expand at 3.6% CAGR between 2024 and 2032. The increasing incidence of organ transplantations and the rising use of sirolimus as an immunosuppressant to prevent organ rejection is driving the industry growth. The rising prevalence of various diseases, such as cancer, lymphangioleiomyomatosis (LAM), and coronary artery disease is spurring the demand for sirolimus-based therapies.

According to data from United Network of Organ Sharing, more than 46,000 organ transplants were performed in the U.S. in 2023. The rising cases of organ transplants is increasing the demand for sirolimus. The ongoing clinical trials investigating the efficacy of sirolimus in treating various medical conditions is increasing their market appeal. Significant advancements in drug delivery technologies and the introduction of generic formulations are enhancing accessibility and affordability, further driving the widespread adoption of sirolimus-based medications.

The sirolimus industry is bifurcated into application, route of administration, dosage, distribution channel, and region.

Based on application, the market size from the Lymphangioleiomyomatosis (LAM) segment is estimated to grow at 3.4% CAGR between 2024 and 2032. This is owing to the lack of effective treatment options for LAM, a rare and progressive lung disease primarily affecting women. Sirolimus has demonstrated efficacy in stabilizing lung function and reducing symptoms in LAM patients. The increasing awareness about sirolimus as a therapeutic option for LAM and the ongoing clinical research will further drive the segment growth.

With respect to route of administration, the sirolimus industry from the injection segment will depict 3.8% CAGR through 2032, due to the rising need for targeted and controlled drug delivery, especially in transplant patients requiring immunosuppression. Injectable formulations of sirolimus offer precise dosing and rapid onset of action, making them suitable for post-transplant care. These injections also ensure systemic distribution of the drug, optimizing therapeutic outcomes. Significant advances in injection technologies for improving patient convenience and compliance will add to the segment growth.

Regionally, the Europe sirolimus market is estimated to depict 3.2% gains from 2024 and 2032, driven by the increasing prevalence of chronic diseases requiring immunosuppressive therapy, including organ transplantations and autoimmune disorders. Additionally, the adoption of sirolimus in oncology for the treatment of various cancers across the region is growing. Moreover, favorable government initiatives supporting organ donation and transplantation, coupled with advancements in healthcare infrastructure will further stimulate the demand for sirolimus-based medications in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of organ transplants
    • 3.2.1.2 Promising pipeline for different indications
    • 3.2.1.3 Advancements in drug delivery systems
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with sirolimus
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Organ transplant rejection
• 5.3 Lymphangioleiomyomatosis (LAM)
• 5.4 Sirolimus coated balloons and catheter devices

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Injection
• 6.3 Tablets

Chapter 7 Market Estimates and Forecast, By Dosage, 2021- 2032 ($ Mn)

• 7.1 Key trends
• 7.2 0.5mg
• 7.3 1mg
• 7.4 2mg

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Accord Healthcare Limited
• 10.2 Apotex Inc.
• 10.3 Amneal Pharmaceuticals, Inc.
• 10.4 Actiza Pharmaceutical Private Limited
• 10.5 Biocon Limited
• 10.6 Concept Medical
• 10.7 Concord Biotech
• 10.8 Dr. Reddy's Laboratories Ltd.
• 10.9 Intas Pharmaceuticals Ltd.
• 10.10 Livzon Pharmaceuticals Group Inc.
• 10.11 Pfizer Inc.
• 10.12 Tiefenbacher API + Ingredients GmbH & Co. KG
• 10.13 Torrent Pharmaceuticals Ltd.
• 10.14 Zydus Group